Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan

Annals of Oncology

Volumn 15, Issue 4, 2004, Pages 618-625

  You, J Y ^a   Chi, K H ^a   Yang, M H ^a   Chen, C C ^a   Ho, C H ^a   Chau, W K ^a   Hsu, H C ^a   Gau, J P ^a   Tzeng, C H ^a   Liu, J H ^a   Chen, P M ^a   Chiou, T J ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Combined modality; Intent to treat; International Prognostic Index (IPI); Nasal NK T cell lymphoma; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NOSE CAVITY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; T CELL LYMPHOMA; TAIWAN; TUMOR BIOPSY;

EID: 2342425819     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh143     Document Type: Article

References (37)

1. Jaffe ES, Chan JK, Su IJ. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphoma: definition, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-111.
2. Oshimi K. NK cell lymphoma. Int J Hematol 2002; 76 (Suppl 2): 118-121.
3. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003; 40: 175-184.
4. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol 2003; 40: 221-232.
5. Sanchez MJ, Spits H, Lanier LL et al. Human natural killer cell committed thymocytes and their relation to the T cell lineage. J Exp Med 1993; 178: 1857-1866.
6. Sanchez MJ, Muench MO, Roncarolo MG et al. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994; 180: 569-576.
7. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103; 216-221.
8. Proulx GM, Caudra-Garcia I, Ferry J et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26: 6-11.
9. Isiksacan V, Topaloglu I, Berkiten G, Peker K. Two cases of nasal natural killer T-cell lymphoma. Kulak Burun Bogaz Ihtis Derg 2002; 9: 376-379.
10. Yong W, Zheng W, Zhang Y. Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma [in Chinese]. Zhonghua Yi Xue Za Zhi 2001; 81: 773-775.
11. Ribrag V, Ell Hajj M, Janot F et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 1123-1126.
12. Amaoui B, Saadi I, El Mourabit A et al. Angiocentric lymphoma of the face: report of the 2 cases [in French]. Cancer Radiother 2003; 7: 314-316.
13. Rodriguez J, Romaguera JE, Manning J et al. Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma 2000; 39: 139-144.
14. Logsdon MD, Ha CS, Kavadi VS et al. Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80: 477-488.
15. Chen HH, Fong L, Su IJ et al. Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: a retrospective analysis covering a 34-year period. Radiother Oncol 1996; 38: 1-6.
16. Aviles A, Neri N, Fernandez R et al. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003; 20: 13-17.
17. Liang R, Chen F, Lee CK et al. Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. Bone Marrow Transplant 1997; 19: 91-93.
18. Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-352.
19. Li YX, Coucke PA, Li JY et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998; 83: 449-456.
20. Kwong YL, Chan ACL, Liang R et al. CD56 + NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821-829.
21. Shikama N, Izuno I, Oguchi M et al. Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy. Radiology 1997; 204: 467-470.
22. Hirakawa S, Kuyama M, Takahashi S et al. Nasal and nasal type natural killer/T-cell lymphoma. J Am Acad Dermatol 1999; 40: 268-272.
23. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1861.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Cox DR. Analysis of Binary Data. London, UK: Methuen 1970.
26. Cox DR. Regression models and life table (with discussion). J R Stat Soc B 1972; 34: 457-481.
27. Cheung MM, Chan JK, Lau WH et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-190.
28. Shikama N, Ikeda H, Nakamura S et al. Localized aggressive nonHodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 2001; 51: 1228-1233.
29. Yamaguchi M, Kita K, Miwa H et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-2356.
30. Fukuda J, Yoshihara T, Arai Y et al. Nasal NK-cell lymphoma. Rinsho Ketsueki 1994; 35: 588-592.
31. van Gorp J, de Bruin P, Sie-Go D et al. Nasal T-cell lymphoma: a clinicopathological and immunophenotypic analysis of 13 cases. Histopathology 1995; 27: 139-148.
32. Izumo T, Maseki N, Mori S, Tsuchiya E. Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas. Jpn J Cancer Res 2000; 91: 351-360.
33. Meusers P, Brittinger G. REAL Classification of non-Hodgkin's lymphoma from the clinico-oncologic viewpoint [in German]. Schweiz Rundsch Med Prax 1998; 87: 793-800.
34. Cortelazzo S, Rossi A, Roggero F et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG). Ann Oncol 1999; 10: 1433-1440.
35. Rudiger T, Weisenburger DD, Anderson JR et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140-149.
36. Lopez-Guillermo A, Cid J, Salar A et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification. Ann Oncol 1998; 9: 849-855.
37. Ansell SM, Habermann TM, Kurtin P et al. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997; 15: 2296-2301.